MiMedx Group Stock Soars 11.35% on Record Q2 Earnings

MiMedx Group's stock surged 11.35% in pre-market trading on July 31, 2025, driven by strong second-quarter financial results that exceeded analyst expectations.

MiMedx Group reported record-breaking financial results for the second quarter of 2025, with net sales reaching $99 million, marking a 13% year-over-year growth. The company's earnings and revenue surprises were +66.67% and +10.45%, respectively, for the quarter ended June 2025. This performance has led to a significant increase in the company's stock price.

The company's strong financial performance has also led to an increase in its net sales growth expectations for 2025, anticipating low double-digit growth for the full year. This positive outlook has further boosted investor confidence in the company's future prospects.

MiMedx Group's record-breaking Q2 2025 results, including the highest quarterly revenue and adjusted EBITDA in the company's history, have solidified its position as a leader in the biotechnology industry. The company's strong financial performance and positive outlook for the future have made it an attractive investment option for many investors.